News on Paclitaxel from BioPortfolio.com http://www.BioPortfolio.com Consolidated Paclitaxel news from BioPortfolio.com Wed, 10 Feb 2010 07:00:41 GMT en Genta commences Phase 2 trial of tesetaxel on first subjecthttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034650&HITNO=0&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034650&THISHREF=http://c.moreover.com/click/here.pl%3fz2535909558%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034650&HITNO=0&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034650&THISHREF=http://c.moreover.com/click/here.pl%3fz2535909558%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Genta commences treatment in tesetaxel Phase 2 trial for advanced melanomahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033220&HITNO=1&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033220&THISHREF=http://c.moreover.com/click/here.pl%3fz2535076243%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033220&HITNO=1&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033220&THISHREF=http://c.moreover.com/click/here.pl%3fz2535076243%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-/Smad activityhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031010&HITNO=2&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031010&THISHREF=http://c.moreover.com/click/here.pl%3fz2533937150%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031010&HITNO=2&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031010&THISHREF=http://c.moreover.com/click/here.pl%3fz2533937150%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comLaboratory Investigation: Stock Hunter Is Hot!! Sign Up Today!! GETA,GOVX,NPWZ,VHGI,RDBO,SHMNhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032004&HITNO=3&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032004&THISHREF=http://c.moreover.com/click/here.pl%3fz2534464898%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032004&HITNO=3&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032004&THISHREF=http://c.moreover.com/click/here.pl%3fz2534464898%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advancedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031630&HITNO=4&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031630&THISHREF=http://c.moreover.com/click/here.pl%3fz2534281602%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031630&HITNO=4&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031630&THISHREF=http://c.moreover.com/click/here.pl%3fz2534281602%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advancedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031575&HITNO=5&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031575&THISHREF=http://c.moreover.com/click/here.pl%3fz2534268838%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031575&HITNO=5&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031575&THISHREF=http://c.moreover.com/click/here.pl%3fz2534268838%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanomahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030110&HITNO=6&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030110&THISHREF=http://c.moreover.com/click/here.pl%3fz2533446623%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030110&HITNO=6&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030110&THISHREF=http://c.moreover.com/click/here.pl%3fz2533446623%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanomahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029666&HITNO=7&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029666&THISHREF=http://c.moreover.com/click/here.pl%3fz2533227500%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029666&HITNO=7&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029666&THISHREF=http://c.moreover.com/click/here.pl%3fz2533227500%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advancedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029639&HITNO=8&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029639&THISHREF=http://c.moreover.com/click/here.pl%3fz2533217390%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029639&HITNO=8&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029639&THISHREF=http://c.moreover.com/click/here.pl%3fz2533217390%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advancedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029380&HITNO=9&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029380&THISHREF=http://c.moreover.com/click/here.pl%3fz2533116751%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029380&HITNO=9&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029380&THISHREF=http://c.moreover.com/click/here.pl%3fz2533116751%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group studyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028713&HITNO=10&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028713&THISHREF=http://c.moreover.com/click/here.pl%3fz2532827041%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028713&HITNO=10&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028713&THISHREF=http://c.moreover.com/click/here.pl%3fz2532827041%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: Everolimus better than paclitaxel when eluted from stentshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019870&HITNO=11&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019870&THISHREF=http://c.moreover.com/click/here.pl%3fz2526499430%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019870&HITNO=11&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019870&THISHREF=http://c.moreover.com/click/here.pl%3fz2526499430%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPJ Online: TopoTarget signs co-development and commercialization agreement with Spectrum Pharmaceuticalshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022677&HITNO=12&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022677&THISHREF=http://c.moreover.com/click/here.pl%3fz2527794765%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022677&HITNO=12&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022677&THISHREF=http://c.moreover.com/click/here.pl%3fz2527794765%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTradingMarkets: TopoTarget Partner, Spectrum Pharmaceuticals, to host Conference Call Thursday 4 February 2010 at 19:00 CET (1http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018412&HITNO=13&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018412&THISHREF=http://c.moreover.com/click/here.pl%3fz2525657571%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018412&HITNO=13&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018412&THISHREF=http://c.moreover.com/click/here.pl%3fz2525657571%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: New adjuvant breast cancer treatments not tied to amenorrheahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4009735&HITNO=14&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4009735&THISHREF=http://c.moreover.com/click/here.pl%3fz2522068051%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4009735&HITNO=14&MSIZE=353&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Paclitaxel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4009735&THISHREF=http://c.moreover.com/click/here.pl%3fz2522068051%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comReuters Health: